May 2023, the community groups in Indonesia organized a protest rally against stock-shortage of direct-acting antivirals used for treatment of hepatitis C. During negotiations at the end of the protest, it was agreed that sofosbuvir/velpatasvir will be added to the national formulary to enable procurements of the same through national programs.
Since December 2023, sofosbuvir/velpatasvir has been added to the national formulary list. Initial procurements will be done through Global Fund grants.